Oncodesign Precision Medicine announces the establishment of an equity financing line of up to €5 million

17 avr. 2025

Oncodesign Precision Medicine has set up a new equity financing line of up to €5 million with IRIS to strengthen its cash position and support the development of its clinical programs amid challenging market conditions.

Dijon, France – apr 17, 2025 – Oncodesign Precision Medicine, a biopharmaceutical company specializing in precision medicine for the treatment of resistant and metastatic cancers, announces the establishment of an equity financing line of up to €5 million.

Download the Press Release (French)